Compositions for protein delivery comprising bile salts and cationic peptides and uses thereof
By using bile acid salts and specific sequence cationic peptide compositions in epithelial tissues, combining fatty acids, the problem of inefficient delivery of target proteins in epithelial tissues is solved, and the efficiency of non-invasive protein delivery is achieved.
Patent Information
- Application Number
- CN202380028824.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-27
- Filing Date
- 2023-03-22
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to effectively deliver protein therapeutic agents to the body by non-invasive methods, especially in epithelial tissues, and the delivery efficiency is low, and the bile acid salts are not effective in vivo delivery of peptides and proteins in normal environments in the individual. Significant.
The composition containing bile acid salt and a specific sequence of cationic peptides is used to selectively add prescribed fatty acids to enhance the penetration of target proteins in epithelial tissues for protein delivery.
It significantly improves the penetration and absorption rate of target proteins in epithelial tissues, realizes non-invasive protein delivery, and is suitable for the prevention or treatment of metabolic diseases, etc.
Smart Images

Figure CN118900685A_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for protein delivery which improves the in vivo absorption rate of a target protein. [Background technology]
[0002] Proteins play various functions in the body, have excellent target specificity, excellent therapeutic effects and few side effects, and are therefore used as therapeutic agents for major diseases such as cancer and diabetes. Depending on the characteristics of the pharmaceutical composition, therapeutic agents can be administered by various routes such as injection, oral administration, inhalation, and mucosal delivery, but protein therapeutic agents, which are high molecular weight compounds, are mainly delivered only by invasive methods such as injection, so there are limitations in terms of administration into the body. However, for various diseases, including intractable diseases that require long-term treatment, a method for non-invasively administering protein therapeutic agents is needed.
[0003] Epithelial tissue is the tissue or composition of glands such as endocrine glands and exocrine glands covering the body surface, body cavity and inner surface of tubular organs of animals. Epithelial tissue plays the role of protecting the body from invasion or external stimulation of foreign substances (e.g., pathogens, foreign proteins, DNA, etc.), is also responsible for receiving and transmitting external stimulation or transporting and exchanging small substances, and also plays various functions according to each organization. However, the delivery efficiency of protein by epithelial tissue is very low. Therefore, various studies are being conducted on bile acid, fatty acid or sabolic sodium (Salcaprozate sodium, SNAC) etc. as various absorption enhancers (absoption enhancer), to improve the delivery efficiency of protein therapeutics using skin tissue or mucous membrane tissue of digestive tract, respiratory tract or genitals.
[0004] On the other hand, bile salts are substances produced in the gallbladder and promote the digestion and absorption of fat by helping the dissolution of fat in the digestive tract, and are ionic amphiphilic compounds with a steroid skeleton. Bile salts, which are similar in structure to the cholesterol matrix, are formed in the liver through enzymatic oxidation, isomerization and reduction of cholesterol. Then, bile salts are chemically bound to one of two amino acids (taurine and glycine) to form "bound" bile acids (L-glycocholate and taurocholate). The bound bile acid molecules secreted during digestion are further chemically modified (dehydroxylated and unbound) by enzymes produced by the intestinal flora to produce various bile acids (Molecules 2015, 20, 14451-14473). Bile acids are classified into trihydroxy bile salts (taurocholate, glycocholate, cholate) or dihydroxybile salts (taurodeoxycholate, glycodeoxycholate, chenodeoxycholate, deoxycholate) according to whether they are hydroxylated or conjugated.
[0005] Previous studies have used bile acids to increase the in vivo delivery efficiency of protein therapeutics. It has been confirmed that mainly conjugate bile salts such as taurocholate or glycocholate effectively deliver peptides such as insulin and salmon calcitonin from the blood-brain barrier, skin mucosa, cornea, intestinal mucosa, etc. to the body. However, most previous studies 1) act as a component in liposomes, nanoparticles, or bile acid bodies, rather than the single effect of bile salts, or 2) only show effects in cell models simulating trans-epitherlial delivery or experimental models directly delivered to the duodenum to eliminate digestion in the stomach. In addition, there are almost no results showing efficacy under normal conditions at the individual level, which shows that the in vivo delivery effect of bile salts alone on peptides and proteins is not significant.
[0006] Therefore, there is a need for novel carriers with excellent in vivo delivery effects for target peptides or proteins. [Summary of the invention]
[0007]
Technical issues
[0008] The present inventors have made great efforts to develop a composition for protein delivery that can increase the permeability of target proteins in epithelial tissues. As a result, it was found that when a composition comprising bile salts and a cationic peptide of a specified sequence, optionally additionally comprising a specified fatty acid, can increase the permeability of target proteins in epithelial tissues, thereby completing the present invention.
[0009] Therefore, an object of the present invention is to provide a composition for protein delivery which has increased penetration in epithelial tissues.
[0010] Another object of the present invention is to provide a percutaneous absorption preparation comprising the above composition for protein delivery.
[0011] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating metabolic diseases, which comprises the above-mentioned composition for protein delivery.
[0012] Another object of the present invention is to provide a health functional food composition, which comprises the above composition for protein delivery.
[0013] Another object of the present invention is to provide a cosmetic composition comprising the above composition for protein delivery.
[0014]
Technical solution
[0015] According to one embodiment of the present invention, the present invention provides a composition for protein delivery, comprising bile salt and one or more selected from the group consisting of peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 34 as effective ingredients.
[0016] The present inventors have made great efforts to develop a composition for protein delivery that can increase the permeability of target proteins in epithelial tissues. As a result, it was found that when a composition comprising bile salts and a cationic peptide of a specified sequence, optionally further comprising a specified fatty acid, is used, the permeability of target proteins in epithelial tissues can be increased.
[0017] The sequences of SEQ ID NO: 1 to SEQ ID NO: 34 of the present invention are shown in Table 1 below.
[0018]
Table 1
[0019]
[0020] When describing the peptide sequence in this specification, capital letters represent L-amino acids, and lowercase letters represent D-amino acids. The amino acid sequence of the present invention may be a sequence mixed with L-form amino acids or D-form amino acids.
[0021] The technical feature of the composition for protein delivery of the present invention is that it contains bile salts and one or more peptides selected from the group consisting of peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 34. The epithelial permeability of the target protein can be increased by mixing the composition containing bile salts and one or more peptides selected from the group consisting of peptides as shown in cationic peptide 31 L-form SEQ ID NO: 1 to SEQ ID NO: 34 with the target protein to be transported in the body and using them, or applying them to the epithelium independently of the above target protein.
[0022] In one embodiment of the present invention, the composition of the present invention increases the permeability of a target protein in epithelial tissue.
[0023] In the present invention, the above-mentioned epithelial tissue is the soft tissue covering the inner wall of the body organs that are in direct contact with the outside of the human body, including all mucus secreting membranes. For example, the respiratory mucosa including the nasal cavity, lungs, etc., the digestive tract mucosa including the oral cavity, sublingual, digestive organ mucosa, genital mucosa including the vagina, urethra, etc., excretory organ mucosa including the anus, or skin tissue.
[0024] The target protein of the present invention is not particularly limited, and various target proteins to be administered into the body can be selected as the transport object.
[0025] In the present invention, the target protein refers to a polymer composed of two or more amino acids through peptide bonds.
[0026] The present invention is characterized in that the delivery effect of the target protein of the above composition in epithelial tissue is not limited to a cargo protein of a specific sequence.
[0027] In one embodiment of the present invention, the size of the target protein of the present invention is 150 kD or less. The composition for protein delivery of the present invention is intended to help the target protein penetrate the epithelium, and the size of the target protein is preferably below a specified size. In the case of a target protein of 150 kD or less, epithelial permeability is confirmed to be significantly increased.
[0028] In one embodiment of the present invention, the target protein of the present invention may be one or more selected from the group consisting of insulin, insulin analogs, glucagon-like peptide-1 (GLP-1) analogs, parathyroid hormone, growth hormone, epidermal growth factor, oligomers and immunoglobulin G (IgG) antibodies, but is not limited thereto. In the case of the above-mentioned GLP-1 analogs, specifically, for example, it may be liraglutide. In the present invention, the bile salt is a bile salt existing in a living body (e.g., trihydroxy bile salt, dihydroxy bile salt), characterized in that it may include one or more selected from the group consisting of taurocholate, glycocholate, cholate, taurodeoxycholate, glycodeoxycholate, deoxycholate, chenodeoxycholate, lithocholate and ursodeoxycholate, but is not limited thereto.
[0029] In the present invention, when the bile salt is a bile salt conjugated with taurine or glycine (eg, taurocholate or glycocholate), it can be particularly effective in increasing or improving the permeability of the target protein in epithelial tissues.
[0030] In the present invention, the cationic peptides can be prepared by conventional peptide synthesis methods known to those skilled in the art, so that the purity of each peptide is above 90%. The peptides can be purchased and used after being commissioned to be prepared by a peptide preparation company.
[0031] In the present invention, the cationic peptide also includes cases where conventional changes that do not significantly change the properties of amino acids occur (for example, substitution of 1 to 2 amino acids, substitution between D-form / L-form, etc.).
[0032] In one embodiment of the present invention, the peptide as an effective ingredient of the present invention can be selected from the group consisting of amino acid sequences in which one or two amino acids in the amino acid sequences shown in SEQ ID NO: 1 to SEQ ID NO: 34 are substituted.
[0033] In one embodiment of the present invention, the composition of the present invention may further comprise fatty acids. As described above, the composition for protein delivery of the present invention comprises bile salts and peptides having a specified amino acid sequence as active ingredients, and when fatty acids are further included, epithelial permeability of the target protein can be further improved.
[0034] In one embodiment of the present invention, the fatty acid of the present invention can be a fatty acid of C4 to C22. More specifically, for example, the fatty acid of the present invention can be a fatty acid of C6 to C22, a fatty acid of C8 to C22, a fatty acid of C10 to C22, a fatty acid of C12 to C22, or a fatty acid of C14 to C20.
[0035] In one specific example of the present invention, the fatty acid of the present invention may be a C16 to C18 fatty acid.
[0036] The above-mentioned fatty acid can be a saturated or unsaturated fatty acid, and more preferably, an unsaturated fatty acid can be used. The unsaturated fatty acid of the present invention refers to a fatty acid containing one or more double bonds, and more preferably, at least one of the one or more double bonds contained in the unsaturated fatty acid of the present invention is a cis double bond.
[0037] The composition for protein delivery according to an embodiment of the present invention may further include phosphate buffer, acetate buffer and / or bicarbonate buffer, but is not limited thereto.
[0038] The composition of one embodiment of the present invention can be administered orally through the skin, sublingually, topically, by patch, or by inhalation, but is not limited thereto.
[0039] The composition of one embodiment of the present invention can be formulated into patch preparations, sprays, ointments, gels, liquids, suppositories, tablets, inhalants, etc. by conventional methods known in the art, but is not limited thereto.
[0040] According to another embodiment of the present invention, the present invention provides a percutaneous absorption preparation comprising the above composition for protein delivery.
[0041] The percutaneous absorbent of the present invention may also contain a target protein to be delivered, and the target protein is as described above. The percutaneous absorbent of the present invention is in the form of a preparation for assisting the percutaneous absorption of the target protein, and may be used for various purposes according to the efficacy of the target protein. Specifically, for example, the percutaneous absorbent of the present invention may be used to supplement a certain protein that causes a certain disease or symptom due to a lack in the body, or may be used to deliver a protein to the body that obtains a certain desired effect by delivery to the body.
[0042] According to another embodiment of the present invention, the present invention provides a pharmaceutical composition for preventing or treating metabolic diseases, which comprises bile salts, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and a protein drug for preventing or treating metabolic diseases as active ingredients.
[0043] The bile salts and one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34 contained in the pharmaceutical composition for preventing or treating metabolic diseases of the present invention have been described in detail as the active ingredients of the above-mentioned composition for protein delivery in another embodiment of the present invention. The pharmaceutical composition of the present invention may contain a protein component having a preventive or therapeutic effect on metabolic diseases as an active ingredient, and the bile salts and peptides having a specified sequence can significantly increase the in vivo absorption of the protein component as an active ingredient of the above-mentioned pharmaceutical composition through the epithelium.
[0044] In one embodiment of the present invention, the composition of the present invention may further include fatty acids. The fatty acids that may be included in the pharmaceutical composition of one embodiment of the present invention correspond to the fatty acids that may be included in the above-mentioned composition for protein delivery as another embodiment of the present invention, and thus repeated descriptions will be omitted.
[0045] In one example of the present invention, the metabolic disease of the present invention can be one or more selected from the group consisting of diabetes, obesity, osteoporosis and growth hormone deficiency, but is not limited thereto. Specifically, for example, when the pharmaceutical composition of the present invention corresponds to a composition for preventing or treating diabetes, insulin, insulin analogs or GLP-1 analogs, etc. may be included as target proteins. Furthermore, when the pharmaceutical composition of the present invention corresponds to a composition for preventing or treating obesity, leptin, Pramlintide, GLP-1 receptor antagonists, liraglutide, etc. may be included as target proteins. Furthermore, when the pharmaceutical composition of the present invention corresponds to a composition for treating osteoporosis, parathyroid hormone, etc. may be included, and the pharmaceutical composition of the present invention includes growth hormone, etc. as an effective ingredient, thereby being helpful in treating growth hormone deficiency or inducing the growth of a subject in the growth stage. The above-mentioned active ingredients are only specific examples. On the one hand, the present invention relates to a pharmaceutical composition, the technical feature of which is to improve the in vivo delivery efficiency of the active ingredients of various protein drugs through the epithelium. There is no particular limitation on the type of target protein as the active ingredient of the pharmaceutical composition.
[0046] In the present invention, the description of the pharmaceutical composition relates to a pharmaceutical composition for administration to humans in principle, but the skilled artisan will understand that such compositions are generally suitable for administration to animals of all kinds. If necessary, there is a good understanding of the modification of pharmaceutical compositions for administration to various animals and a skilled veterinary pharmacologist can design and / or perform such modifications by routine experiments.
[0047] In the present invention, the pharmaceutical composition can also be prepared by methods known in the field of pharmacology or any method described in the following content. Generally, this method for tablets includes the steps of combining the active ingredient with excipients and / or one or more auxiliary ingredients, and then includes the steps of molding and / or packaging the product into the desired single dose or multiple dose units as needed or required.
[0048] In the present invention, the pharmaceutical composition may also be prepared, packaged, and / or sold in an unpackaged state as a single unit dose and / or a plurality of single unit doses.
[0049] A "unit dose" is a single amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of active ingredient is the same as the amount of active ingredient administered to a subject and / or a convenient fraction of such an amount, such as 1 / 2 or 1 / 3 of the amount.
[0050] In the present invention, the relative amounts of the active ingredient, pharmaceutically acceptable excipient and / or any additional ingredients in the pharmaceutical composition can be appropriately adjusted according to the identity, size and / or degree of disease of the subject to be treated and the route of administration of the composition. Specifically, for example, the pharmaceutical composition of an example of the present invention can also contain 0.1% to 100% (w / w) of the active ingredient.
[0051] In the present invention, pharmaceutically acceptable excipients include any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersions or suspending agents, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. suitable for the purpose of a specific administration form. Remington's literature [The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro, (Lippincott, Williams & Wilkins, Baltimore, MD, 2006] discloses various excipients for preparing pharmaceutical compositions and known techniques for preparing them. Except for, for example, providing any undesirable biological effects or interacting with any other ingredients of the pharmaceutical composition in a harmful manner, thereby being unable to coexist with the substance or its derivatives, the use of any common carrier medium is considered to be within the scope of the present invention. The purity of the pharmaceutically acceptable excipient is at least 95%, 96%, 97%, 98%, 99% or 100%.
[0052] The above excipients are approved for human and veterinary use. In some embodiments, the excipient is approved by the U.S. Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia and / or the International Pharmacopoeia (EP). In some embodiments, the excipient is approved for human and veterinary use.
[0053] Pharmaceutically acceptable excipients used in the preparation of pharmaceutical compositions include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils, but are not limited thereto.
[0054] Such excipients may be optionally included in the formulations of the present invention. Excipients such as cocoa butter, suppository waxes, coloring agents, coating agents, sweetening agents, flavoring agents and perfuming agents may be present in the composition according to the judgment of the formulator.
[0055] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium lactose phosphate, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and combinations thereof, but are not limited thereto.
[0056] According to another embodiment of the present invention, the present invention provides a health functional food composition, which comprises bile salts, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and health functional proteins as effective ingredients.
[0057] In one embodiment of the present invention, the composition of the present invention may further include fatty acids. The fatty acids included in the health functional food composition of one embodiment of the present invention correspond to the fatty acids included in the composition for protein delivery of another embodiment of the present invention.
[0058] The health functional food composition of the present invention may contain protein components as various effective ingredients acceptable in food science, and may have the effect of preventing or improving various diseases or body dysfunctions.
[0059] The health functional food composition of the present invention comprises ingredients commonly added during food preparation, for example, including proteins, carbohydrates, fats, nutrients and flavoring agents. For example, when prepared as a drink, in addition to the active ingredients, flavoring agents or natural carbohydrates may be included as additional ingredients. For example, natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); disaccharides (e.g., maltose, sucrose, etc.); oligosaccharides; polysaccharides (e.g., dextrin, cyclodextrin, etc.); and sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.).
[0060] As the flavoring agent, natural flavoring agents (eg, thaumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be used.
[0061] According to another embodiment of the present invention, the present invention provides a cosmetic composition comprising bile salt, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and a functional protein as effective ingredients.
[0062] In one embodiment of the present invention, the composition of the present invention may further include fatty acids. The fatty acids included in the cosmetic composition of one embodiment of the present invention correspond to the fatty acids included in the composition for protein delivery of another embodiment of the present invention.
[0063] The cosmetic composition of the present invention may contain a protein component as various cosmetically acceptable active ingredients, and may have a preventive or ameliorative effect on various diseases or body dysfunctions. The above effects are not limited to diseases or body dysfunctions observed on the epithelium, and the present invention may be applied to more diverse diseases or body dysfunctions as long as it has the ability to penetrate the skin.
[0064] The cosmetic composition of the present invention can be prepared into any dosage form commonly prepared in this field, for example, it can be formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, lotion containing surfactant, oil, powder foundation, emulsion foundation, wax foundation and spray, but it is not limited thereto. More specifically, it can be prepared into a soft lotion, nourishing lotion, lotion, nourishing cream, massage cream, essence, eye cream, makeup remover, cleanser, makeup remover, sheet mask, spray or powder dosage form.
[0065] When the dosage form of the present invention is a paste, cream, emulsion or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicon, bentonite, silicon dioxide, talc or zinc oxide can be used as a carrier component.
[0066] When the dosage form of the present invention is a powder or a spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component. In particular, when the dosage form of the present invention is a spray, it can further contain a propellant such as chlorofluorocarbons, propane / butane or dimethyl ether.
[0067] When the dosage form of the present invention is a solution or an emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, for example, including water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol fatty acid ester, polyethylene glycol or alcohol fatty acid ester of sorbitan.
[0068] When the dosage form of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth gum, etc. can be used as carrier components.
[0069] When the dosage form of the present invention is a lotion containing a surfactant, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazoline derivatives, taurine methyl ester, sarcosinates, fatty acid amide ether sulfates, alkylamide betaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glyceryl fatty acid esters can be used as carrier components.
[0070] In addition to the active ingredients and carrier components, the ingredients contained in the cosmetic composition of the present invention also include ingredients commonly used in cosmetic compositions, for example, conventional auxiliary agents such as antioxidants, stabilizers, cosolvents, vitamins, pigments and fragrances may be contained.
[0071] [Effects of the invention]
[0072] (a) The present invention provides a composition for protein delivery that has increased penetration in epithelial tissues.
[0073] (b) The present invention provides a percutaneous absorption preparation comprising the above composition for protein delivery.
[0074] (c) The present invention provides a pharmaceutical composition for preventing or treating metabolic diseases, which comprises the above composition for protein delivery.
[0075] (d) The present invention provides a health functional food composition comprising the above composition for protein delivery.
[0076] (e) The present invention provides a cosmetic composition comprising the above composition for protein delivery.
[0077] (f) When the composition for protein delivery of the present invention is used, the target protein can be effectively delivered into the body in a non-invasive manner (non-injectable dosage form) by increasing the permeability of the target protein as a polymer to epithelial tissue and transdermal tissue.
[0078] Therefore, the advantages of the above composition are that it can be used to prevent or treat metabolic diseases including diabetes and obesity, and can be applied to cosmetics and health functional foods, etc.
Brief Description of the Drawings
[0079] Figure 1 The changes in the insulin absorption rate in epithelial tissues according to bile salts and / or cationic peptides are shown. The degree of biological absorption of insulin is expressed by the blood glucose lowering effect after administration. Compared with the insulin containing no bile salts and cationic peptides or containing only bile salts (TC: taurocholate, Figure 1 A portion of) or a cationic peptide (SEQ6, Figure 1 Compared with the case of one of the above (part A), when bile salts (e.g., taurocholate) and cationic peptides (e.g., SEQ6) are simultaneously included, insulin absorption in skin and mucosal tissues is significantly increased. Moreover, compared with the case of not including bile salts and cationic peptides or only including bile salts (TC: taurocholate, Figure 1 B part) or a cationic peptide (SEQ6, Figure 1Compared with one of the cases in Part C of the present invention, insulin absorption in the sublingual mucosal tissue was significantly increased.
[0080] Figure 2 The figure shows the changes in the insulin absorption rate when orally administered according to bile salts and / or cationic peptides. The degree of biological absorption of insulin is represented by the blood glucose lowering effect after administration. When the cationic peptide (SEQ6, Figure 2 Part A, SEQ2, Figure 2 When the insulin mixture (part B) was mixed with bile salts, insulin absorption was significantly increased in a cationic peptide concentration-dependent manner.
[0081] Figure 3 The absorption rate of insulin in sublingual mucosal tissue according to the mixed composition of different kinds of cationic peptides and bile acid salts is shown. The biological absorption degree of insulin is expressed by the blood sugar lowering effect after administration.
[0082] Figure 4 The absorption rate of insulin in sublingual mucosal tissues is shown based on bile salts and cationic peptides composed of D-form or L-form amino acids. The degree of biological absorption of insulin is expressed by the blood sugar lowering effect after administration.
[0083] Figure 5 The absorption rate of insulin in sublingual mucosal tissue according to the mixed composition of different types of bile salts and cationic peptides is shown. The degree of biological absorption of insulin is expressed by the blood sugar lowering effect after administration (TC: taurocholate, GC: glycocholate, CdOC: chenodeoxycholate, dOC: deoxycholate).
[0084] Figure 6 The absorption rate of various insulin analogs in sublingual mucosal tissue is shown. The degree of biological absorption of insulin is expressed by the blood sugar lowering effect after administration.
[0085] Figure 7 The figure shows the changes in the absorption rate of insulin in the sublingual mucosal tissue (Part A) and the blood sugar lowering effect caused by the biological absorption of insulin when orally administered (Part B) in a type 1 diabetes mouse model. 30 mM taurocholate and 1 μM SEQ6 were used as absorption enhancing compositions.
[0086] Figure 8The figure shows changes in the absorption rate of insulin when applied to the skin depending on the mixed composition of bile salt (taurocholate) and cationic peptide (SEQ6). The degree of biological absorption of insulin is expressed by the blood sugar lowering effect after administration.
[0087] Fig. 9 The graph shows changes in liraglutide absorption rate in sublingual mucosal tissue depending on the mixed composition of bile salt (taurocholate) and cationic peptide (SEQ6).
[0088] Fig.10 The absorption rate of insulin in sublingual mucosal tissue according to cationic peptides represented by different amino acid sequences is shown. The degree of biological absorption of insulin is expressed by the blood sugar lowering effect after administration.
[0089] Fig.11 The graph shows changes in the absorption rate of epithelial cell growth factor in nasal mucosal tissue depending on the mixed composition of bile salt (taurocholate) and cationic peptide (SEQ14).
[0090] Fig.12 The figure shows the change in the absorption rate of human growth hormone in the nasal mucosal tissue depending on the mixed composition of bile salt (taurocholate) and cationic peptide.
[0091] Fig.13 The figure shows the changes in the absorption rate of human antibodies (IgG) in the nasal mucosal tissue according to the mixed composition of bile salts (taurocholate) and cationic peptides, measured by the hIgG concentration in plasma 3 hours after administration to mice (Part A), and the comparison of the blood concentrations of the same dose of nasal administration and subcutaneous injection is shown (Part B).
[0092] Fig.14 The effect of pH of a mixed composition on protein delivery of a mixed composition of bile salt (taurocholate) and a cationic peptide is shown.
[0093] Fig.15 The figure shows the changes in the insulin absorption rate in the nasal mucosal tissue according to the mixed composition of bile salt (taurocholate), fatty acid (oleic acid) and cationic peptide. Part A shows the changes in blood sugar after administration, and Part B shows the changes in measured insulin.
[0094] Fig.16The results show changes in insulin delivery efficiency according to mixed compositions of bile salts (taurocholate) mixed with various fatty acids and cationic peptides. Fig.16 A part) and unsaturated fatty acids ( Fig.16 The B part) can cause changes in delivery efficiency depending on the chain length of the hydrocarbon and the presence or absence of double bonds.
[0095] Fig.17 The graph shows the plasma concentration of parathyroid hormone 34 (PTH) 15 minutes after administration to the nasal mucosal tissue according to a mixed composition of bile salt (taurocholate), fatty acid (oleic acid), and cationic peptide (SEQ14).
[0096] Fig.18 The graph shows the plasma concentration of human growth hormone (hGH) 15 minutes after administration to the nasal mucosal tissue according to the mixed composition of bile salt (taurocholate), fatty acid (oleic acid), and cationic peptide (SEQ14).
[0097] Fig.19 The plasma concentration of human antibody IgG (hIgG) 3 hours after administration of a mixed composition of bile salt (taurocholate (TC), fatty acid (oleic acid (OA)) and cationic peptide (SEQ14) to nasal mucosal tissue is shown. [Specific implementation method]
[0098] Hereinafter, the present invention will be described in detail.
[0099] Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as those commonly understood by those skilled in the art to which the invention belongs. Generally, the nomenclature used in this specification uses methods well known and commonly used in the art.
[0100] [Example]
[0101] [Example 1: Confirmation that the Insulin Absorption Rate in Sublingual Mucosal Tissue Is Increased by Bile Salts and Cationic Peptides]
[0102] The changes in the insulin absorption rate in the sublingual mucosal tissue according to bile salts and / or peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 18 were studied. All cationic peptides used in the experiment were synthesized by ANYGEN CO., LTD. The absorption rate of insulin was expressed by measuring the blood sugar drop rate after insulin administration. The experimental groups were as follows:
[0103] (1) TC: 100 mM taurocholate (Sigma-Aldrich Korea, South Korea), (2) Ins+TC: 100 mM taurocholate + 2 U / kg dose of insulin (Humulin N and Eli Lilly Korea, South Korea), (3) Ins+TC+SEQ6: 100 mM taurocholate + 2 U / kg dose of insulin + 1 μM SEQ6, (4) SEQ6: 1 μM SEQ6, (5) Ins+SEQ6: 1 μM SEQ6 + 2 U / kg dose of insulin, (6) TC+Ins+SEQ6: 100 mM taurocholate + 1 μM SEQ6 + 2 U / kg dose of insulin.
[0104] Specifically, anesthesia was performed by intraperitoneal administration of ketamine / xylazine (100 mg / kg, 10 mg / kg, respectively) (BKPharm, Korea) to C57BL / 6 mice (Orientbio Inc., Korea) that maintained normal blood sugar. After confirming that anesthesia was stably completed, blood sugar was measured using an Accuchek blood glucose meter before administration of bile salts and / or cationic peptides and insulin. For each experimental group, a solution of 10 μl of administration volume was administered to the sublingual mucosa, and then blood sugar changes at different times were measured.
[0105] As a result, it was confirmed that when taurocholate or SEQ6 was administered alone, the blood sugar lowering rate caused by insulin was low, but when taurocholate and SEQ6 were administered together, the blood sugar lowering rate caused by insulin was significantly increased ( Figure 1 Part A and Figure 1 This indicates that when taurocholate and SEQ6 are co-administered, the absorption rate of insulin through the sublingual mucosal tissue is significantly increased.
[0106] It has been confirmed that, although there are differences in degree according to the chain length of cationic peptides, they all increase the insulin absorption rate ( Figure 3 ). In addition, it was shown that the insulin absorption rate was better when the amino acids of the cationic peptide were in the D-form than when they were in the L-form ( Figure 4 ).
[0107] It has been confirmed that although there are differences in degree depending on the type of bile salt, all of them increase the insulin absorption rate ( Figure 5 ). In addition, it has been confirmed that bile salts and cationic peptides increase the absorption rate of not only insulin but also various insulin analogs ( Figure 6 ).
[0108] [Example 2: Confirmation that the insulin absorption rate during oral administration is increased by bile salts and cationic peptides]
[0109] The changes in the absorption rate of insulin when orally administered were studied according to bile salts and / or peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 18. The absorption rate of insulin was expressed by measuring the rate of decrease in blood glucose after administration of insulin. The experimental groups were as follows:
[0110] (1) Ins+TC: 100 mM taurocholate + 2 U / kg insulin, (2) Ins+TC+SEQ6: 100 mM taurocholate + 2 U / kg insulin + 10 μM SEQ6, (3) Ins+TC+SEQ6: 100 mM taurocholate + 2 U / kg insulin + 1 μM SEQ6, (4) Ins+TC+SEQ6: 100 mM taurocholate + 2 U / kg insulin + 0.1 μM SEQ6, (5) Ins+TC+SEQ2: 100 mM taurocholate + 2 U / kg insulin + 100 μM SEQ2, (6) Ins+TC+SEQ2: 100 mM taurocholate + 2 U / kg insulin + 100 μM SEQ2 cholate)+2U / kg insulin+10μM SEQ2, (7) Ins+TC+SEQ6: 100mM taurocholate+2U / kg insulin+1μM SEQ2.
[0111] Specifically, C57BL / 6 mice with normal blood sugar were prepared, and blood sugar was measured using an Accuchek blood glucose meter before administration of bile salts and / or cationic peptides and insulin. Bile salts and / or cationic peptides and insulin were directly administered using a zonde, and then blood sugar changes at different times were measured.
[0112] As a result, it was confirmed that the cationic peptide had a blood sugar lowering effect caused by insulin in a concentration-dependent manner ( Figure 2 Part A and Figure 2 Part B of the
[0113] [Example 3: Confirmation that the insulin absorption rate in the type 1 diabetes mouse model is increased by bile salts and cationic peptides]
[0114] In a type 1 diabetic mouse model treated with streptozotocin, changes in the insulin absorption rate in the sublingual mucosal tissue according to bile salts and / or peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 18 were studied. Specifically, for C57BL / 6 mice used in the experiment, streptozotocin (Sigma Aldrich Korea, Korea) was dissolved in citrate buffer (100 mM, pH 4.5) and administered at a dose of 150 mg / kg before the experiment, and the mice were allowed free access to feed 6 hours later. Then, blood sugar was measured at the same time every morning, and mice showing a blood sugar level of 400 mg / dl for more than 3 consecutive days were judged to be induced with diabetes and used in the experiment.
[0115] As a result, it was confirmed that bile salts and cationic peptides were administered together with insulin to the sublingual mucosal tissue ( Figure 7 Part A) and oral administration ( Figure 7 Part B) all effectively lowered blood glucose in a concentration range similar to that of normoglycemic mice ( Figure 7 ).
[0116] [Example 4: Confirmation that the insulin absorption rate in the type 1 diabetes mouse model is increased by bile salts and cationic peptides]
[0117] The changes in the absorption rate of insulin when applied to the skin according to bile salts and / or peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 18 were studied. The absorption rate of insulin was expressed by measuring the blood sugar decrease rate after the administration of insulin. Specifically, the back of C57BL / 6 mice that maintained normal blood sugar was depilated using a depilatory cream one day before the experiment. On the day of the experiment, anesthesia was performed by intraperitoneal administration of ketamine / xylazine (100 mg / kg and 10 mg / kg, respectively). After confirming that anesthesia was stably completed, blood sugar was measured using an Accuchek blood glucose meter before the administration of bile salts and / or cationic peptides and insulin. A dosage volume of 50 μl was applied to the depilated skin, and then the changes in blood sugar at different times were measured.
[0118] As a result, when applied to the skin, it has an excellent blood sugar lowering effect caused by insulin in an insulin concentration-dependent manner ( Figure 8 ).
[0119] [Example 5: Confirmation that the absorption rate of liraglutide in sublingual mucosal tissue is increased by bile salts and cationic peptides]
[0120] The absorption rate of liraglutide (Victorza pen-test syringe and Novo Nordisk Pharmaceuticals, Korea) in sublingual mucosal tissue was studied according to changes in bile salts and / or peptides as shown in SEQ ID NO: 1 to SEQ ID NO: 18. The absorption rate of liraglutide was expressed by measuring the glucose tolerance improved by liraglutide. Specifically, anesthesia was performed by intraperitoneal administration of ketamine / xylazine (100 mg / kg, 10 mg / kg, respectively) to C57BL / 6 mice maintaining normal blood sugar. After confirming that anesthesia was stably completed, blood sugar was measured using an Accuchek blood glucose meter before administering bile salts and / or cationic peptides and liraglutide. 10 μl of liraglutide was administered to the sublingual mucosa, and then 1 g / kg of glucose was injected intraperitoneally. The changes in blood sugar at different times were then measured.
[0121] As a result, it was confirmed that liraglutide has an excellent glucose tolerance-improving effect in a concentration-dependent manner ( Fig. 9 ).
[0122] [Example 6: Confirmation that the absorption rate of epithelial cell growth factor in nasal mucosal tissue increases with bile salts and cationic peptides]
[0123] The changes in the absorption rate of epithelial cell growth factor in the nasal mucosal tissue according to bile salts and / or peptides shown as SEQ ID NO: 1 to SEQ ID NO: 34 were studied. All cationic peptides used in the experiment were synthesized by ANYGEN CO., LTD. Epithelial cell growth factor was purchased from recombinant human EGF (recombinant human EGF) of Gibco (GIBCO, USA) and used. The absorption rate of epithelial cell growth factor (EGF) was expressed by collecting blood from the eye socket after administering EGF and separating the plasma, and then measuring the concentration of EGF in the plasma using a human ELISA kit (human ELISA kit, R&D systems, USA). The experimental groups are as follows:
[0124] (1) EGF: EGF was dissolved in 100 mM acetate buffer at pH 4.5 and administered intranasally at 30 μg / kg. (2) EGF+SEQ14: The same amount of EGF was dissolved in the same buffer and administered intranasally together with 10 μM SEQ14. (3) EGF+TC+SEQ14: The same amount of EGF was dissolved in the same buffer and administered intranasally together with 30 mM taurocholate and 10 μM SEQ14.
[0125] Specifically, 8-week-old C57BL / 6 mice (Orientbio Inc., South Korea) were anesthetized by intraperitoneal administration of ketamine / xylazine (100 mg / kg, 10 mg / kg, respectively) (BKPharm, South Korea). After confirming that anesthesia was stably completed, for each experimental group, a 10 μl administration volume of the solution was directly administered into the nostril, and after 5 minutes and 60 minutes, blood was collected from the eye socket using a capillary coated with heparin and plasma was separated. The determination was performed according to the manufacturer's instructions of the ELISA kit and is presented as a bar graph ( Fig.11 As a result, it was confirmed that, similar to insulin, when taurocholate and SEQ14 were administered together, the level of EGF in plasma increased significantly.
[0126] [Example 7: Confirmation that the absorption rate of human growth hormone in nasal mucosal tissue is increased by bile salts and cationic peptides]
[0127] The absorption rate of human growth hormone (hGH, 22 kDa) in nasal mucosal tissue was studied according to changes in bile salts and / or peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34. All cationic peptides used in the experiment were synthesized by ANYGEN CO., LTD. Human growth hormone was Eutropin injection purchased from LG Chemical, and the absorption rate of the administered protein was expressed by collecting blood from the orbit after the administration of the protein and separating the plasma, and then measuring the concentration of the administered protein in the plasma using a human Growth hormone ELISA kit (human Growth hormone ELISA kit, R&D systems, USA). The experimental groups are as follows:
[0128] (1) hGH: human growth hormone was dissolved in 100 mM acetate buffer at pH 4.5 and administered intranasally at 330 μg / kg. (2) hGH+SEQ14: the same amount of EGF was administered intranasally together with 10 μM SEQ14 in the same buffer. (3) hGH+TC: the same amount of human growth hormone was administered intranasally together with 30 mM taurocholate in the same buffer. (4) hGH+TC+SEQ14: the same amount of human growth hormone was administered intranasally together with 30 mM taurocholate and 10 μM SEQ14 in the same buffer.
[0129] Specifically, 8-week-old C57BL / 6 mice (Orientbio Inc., South Korea) were anesthetized by intraperitoneal administration of ketamine / xylazine (100 mg / kg, 10 mg / kg, respectively) (BKPharm, South Korea). After confirming that anesthesia was stably completed, for each experimental group, a 10 μl administration volume of the solution was directly administered into the nostril, and after 15 minutes, blood was collected from the eye socket using a capillary coated with heparin and plasma was separated. The determination was performed according to the manufacturer's instructions of the ELISA kit and is presented as a bar graph ( Fig.12 As a result, it was confirmed that when taurocholate and SEQ14 were administered together, the level of GH in plasma increased significantly. In addition, in order to further confirm the delivery improvement efficiency of the cationic peptides of SEQ19 to SEQ26, when the experimental group was prepared by replacing only the peptides in the previous group 4) with SEQ19 to 26 and tested, it was confirmed that the peptides of SEQ22 to 26 showed a significant improvement effect ( Fig.12 Part B of the
[0130] [Example 8: Confirmation that the absorption rate of human antibody IgG in nasal mucosal tissue increases with bile salts and cationic peptides]
[0131] The absorption rate of human antibody IgG (hIgG, 150 kDa) in nasal mucosal tissue was studied according to the change of bile salts and / or peptides shown as SEQ ID NO: 1 to SEQ ID NO: 34. All cationic peptides used in the experiment were synthesized by ANYGENCO., LTD. Human antibody IgG was purchased from Sigma-Aldrich Korea (South Korea). The absorption rate of the administered protein was expressed by collecting blood from the orbit after the administration of the protein and separating the plasma, and then measuring the concentration of the administered protein in the plasma using human IgG total ELISA (human IgG total ELISA) of Invitrogen (USA). The experimental groups are as follows:
[0132] (1) hIgG: human growth hormone was dissolved in 100 mM acetate buffer at pH 4.5 and administered intranasally at 3.3 mg / kg. (2) hIgG+SEQ14: the same amount of hIgG was administered intranasally together with 10 μM SEQ14 in the same buffer. (3) hIgG+TC: the same amount of hIgG was administered intranasally together with 30 mM taurocholate in the same buffer. (4) hIgG+TC+SEQ14: the same amount of hIgG was administered intranasally together with 30 mM taurocholate and 10 μM SEQ14 in the same buffer.
[0133] Specifically, 8-week-old C57BL / 6 mice (Orientbio Inc., South Korea) were anesthetized by intraperitoneal administration of ketamine / xylazine (100 mg / kg, 10 mg / kg, respectively) (BKPharm, South Korea). After confirming that anesthesia was stably completed, for each experimental group, a 10 μl administration volume of the solution was directly administered into the nostril, and after 3 hours, blood was collected from the eye socket using a capillary coated with heparin and plasma was separated. The determination was performed according to the manufacturer's instructions of the ELISA kit and is presented as a bar graph ( Fig.13 ). As a result, it was confirmed that when taurocholate and SEQ14 were administered together, the level of hIgG in plasma increased significantly. In addition, in order to compare the efficiency of nasal administration and injection of hIgG, it was divided into a non-administration group (control group), a hIgG subcutaneous injection group (SC), and a hIgG nasal administration group, and then plasma was obtained after 3 hours and 6 hours. When injected subcutaneously, hIgG was administered together with PBS. Therefore, it can be confirmed that the increase in IgG in the blood during nasal administration is significantly higher than that during subcutaneous injection ( Fig.13Part B of the
[0134] [Example 9: Confirmation that the Insulin Absorption Rate in Nasal Mucosal Tissue Increases by Bile Salts, Fatty Acids and Cationic Peptides]
[0135] It is well known that bile salts form micelles above a specified concentration, and form larger micelles when mixed with fatty acids. Therefore, it was confirmed whether the significant protein absorption increase effect caused by bile salts and cationic peptides was also observed in the bile salt, fatty acid and cationic peptide composition. The experiment was conducted by an experiment on the reduction of blood sugar due to nasal administration of insulin, and the fatty acid used was oleic acid purchased from Sigma Aldrich Korea. The experimental groups are as follows:
[0136] (1) Control: 15 mM taurocholate and 10 μM SEQ14 were dissolved in 100 mM acetate at pH 4.5 and administered intranasally; (2) Ins: 1 U / kg insulin was dissolved in 100 mM acetate at pH 4.5 and administered intranasally; (3) Ins+SEQ14: 1 U / kg insulin and 10 μM SEQ14 were dissolved in 100 mM acetate at pH 4.5 and administered intranasally; (4) Ins+TC+OA: 1 U / kg insulin, 15 mM taurocholate, 5 mM oleic acid, (5) Ins+TC+OA+SEQ14: 1U / kg dose of insulin, 15mM taurocholate, 5mM oleic acid, and 10μM SEQ14 were dissolved in 100mM acetate at pH 4.5 and administered intranasally.
[0137] Specifically, C57BL / 6 mice with normal blood sugar were prepared, and blood sugar was measured using an Accuchek blood glucose meter before administering the experimental solution. 10 μl of the solution of the above experimental group was directly administered to one nostril of the mouse using a micropipette, and then the changes in blood sugar at different times were measured. As a result, it was confirmed that the mixed composition of bile acid, fatty acid and cationic peptide had a significant blood sugar lowering effect ( Fig.15 Part A). Plasma was obtained 15 minutes after administration under the same experimental conditions, and when measured by human insulin ELISA (ALPCO, USA), it was confirmed that ( Fig.15 Part B of the
[0138] [Example 10: Confirmation that the insulin absorption rate in the nasal mucosal tissue increases depending on the type of fatty acid in the bile salt, fatty acid and cationic peptide composition]
[0139] In order to confirm the effect of fatty acid type, (1) 1U / kg insulin, 15mM taurocholate, and 5mM oleic acid were dissolved in 100mM acetate at pH 4.5 to form a nasal administration experimental group and an experimental group with 5mM fatty acid added. The fatty acids required for the experiment were purchased from Sigma-Aldrich. Butyric acid (4:0), decanoic acid (10:0), palmitic acid (16:0), and stearic acid (18:0) were used as saturated fatty acids, and myristoleic acid (14:1), palmitoleic acid (16:1), oleic acid (18:1), and linoleic acid (18:2) were used as unsaturated fatty acids. Specifically, C57BL / 6 mice that maintain normal blood sugar were prepared, and blood sugar was measured using an Accuchek blood glucose meter before administering the experimental solution. 10 μl of the solution of the above experimental group was directly administered to one nostril of the mouse using a micropipette, and then blood sugar changes at different times were measured. As a result, it can be seen that when C16 to C18 fatty acids are included and are unsaturated fatty acids rather than saturated fatty acids, the insulin delivery effect through the bile salt and cationic peptide composition is the best.
Claims
1. A composition for protein delivery, comprising bile salts and one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34 as active ingredients.
2. The composition for protein delivery according to claim 1, wherein the composition enhances the penetration of a target protein in epithelial tissue.
3. The composition for protein delivery according to claim 2, wherein the size of the target protein is 150 kD or less.
4. The composition for protein delivery according to claim 2, wherein the target protein is one or more selected from the group consisting of insulin, insulin analogs, glucagon-like peptide-1 analogs, parathyroid hormone, growth hormone, epidermal growth factor, oligomers and immunoglobulin G antibodies.
5. The composition for protein delivery according to claim 1, wherein the bile salt comprises one or more selected from the group consisting of taurocholate, glycocholate, cholate, taurodeoxycholate, glycodeoxycholate, deoxycholate, chenodeoxycholate, lithocholate and ursodeoxycholate.
6. The composition for protein delivery according to claim 1, wherein the peptide is selected from the group consisting of amino acid sequences in which one or two amino acids in the amino acid sequences shown in SEQ ID NO: 1 to SEQ ID NO: 34 are substituted.
7. The composition for protein delivery according to claim 1, wherein the composition further comprises a fatty acid.
8. The composition for protein delivery according to claim 7, wherein the fatty acid is a C4 to C22 fatty acid.
9. The composition for protein delivery according to claim 8, wherein the fatty acid is a C16 to C18 fatty acid.
10. A percutaneous absorption preparation comprising the composition for protein delivery according to any one of claims 1 to 9.
11. A pharmaceutical composition for preventing or treating metabolic diseases, comprising bile salts, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and a protein drug for preventing or treating metabolic diseases as active ingredients.
12. The pharmaceutical composition for preventing or treating metabolic diseases according to claim 11, wherein the composition further comprises fatty acid.
13. The pharmaceutical composition for preventing or treating a metabolic disease according to claim 11, wherein the metabolic disease is one or more selected from the group consisting of diabetes, obesity, osteoporosis and growth hormone deficiency.
14. A health functional food composition comprising bile salts, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and a health functional protein as effective ingredients.
15. The health functional food composition according to claim 14, wherein the composition further comprises fatty acid.
16. A cosmetic composition comprising bile salt, one or more peptides selected from the group consisting of peptides shown in SEQ ID NO: 1 to SEQ ID NO: 34, and a functional protein as effective ingredients.
17. The cosmetic composition of claim 16, wherein the composition further comprises a fatty acid.
